Roche (RHHBY) closed at $57.12 on Oct 16, 2026, up 0.6% on the day. The stock is up 4.6% over the past month, up 12.0% over three months, up 14.3% year to date and up 32.5% over the past year. It trades 3.2% below its 52-week high of $58.98 and 47.1% above its 52-week low of $38.84. The close sits above its 50-day moving average ($54.90) and above its 200-day moving average ($52.92).
NextPick tracks RHHBY in its Pharma basket alongside JNJ, ABBV, MRK, NVS and AZN. As of Oct 16, 2026, the basket's money-flow score is -5 (neutral), and the basket is up 3.1% over five sessions. Over the past month RHHBY ranks 5th of 12 basket members by price change.
RHHBY is scheduled to report earnings on Oct 22, 2026. Over its last 1 report the stock moved an average of 1.2% on the first trading day after earnings.
Roche is scheduled to report on Oct 22, 2026.
Over the last 1 report, RHHBY moved an average of 1.2% on the first trading day after earnings.
Yes — the Oct 16, 2026 close of $57.12 is 7.9% above the 200-day average of $52.92.
RHHBY closed 3.2% below its 52-week high of $58.98.
NextPick groups RHHBY with JNJ, ABBV, MRK, NVS and AZN in its Pharma basket.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
